Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Noninferiority trials, or clinical studies meant to show that a new treatment approach is as good as (or superior to) an existing therapeutic comparator, are important in the world of oncology, and...
View ArticleOutcomes With Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia in...
Nilotinib may be a promising frontline therapy for patients with chronic myeloid leukemia in chronic phase (CML-CP), according to study results reported in the British Journal of Haematology. In this...
View ArticleStudy Compares Quality of Life for Patients With Chronic Myeloid Leukemia...
Patients with newly diagnosed chronic myeloid leukemia (CML) treated in the front-line setting with the tyrosine kinase inhibitor (TKI) dasatinib experience better health-related quality of life...
View ArticleCognitive Impairment Following Immunotherapy Treatment May Be Underestimated
It’s well known that chemotherapy treatment can negatively impact a patient’s learning, memory, and other cognitive functions, a condition informally known as “chemo brain.” However, the potential...
View ArticleBlast Count Prognostic for CML Presenting in Advanced Phase
(HealthDay News) — Blast count seems to be the main prognostic count for patients with chronic myeloid leukemia (CML) presenting in an advanced phase, according to a study published online Aug. 27 in...
View ArticlePathologists Need Better Reporting Guidelines for Postneoadjuvant...
A paper published in Modern Pathology in August 20191 called attention to the lack of standardized reporting practices that pathologists use to evaluate postneoadjuvant chemotherapy specimens. The...
View ArticleSome Targeted Therapies May Miss the Mark
When coauthors Ann Lin and Christopher Giuliano, then at Stony Brook University in New York, saw their lab results, they were worried. “We were both undergrads at the time,” said Lin. “It was our...
View ArticleThe Disappointing Reality of Crowdfunding Cancer Care
Like many health care providers, urologist Andrew J. Cohen, MD, had heard anecdotal stories of patients using crowdfunding sites like GoFundMe to raise money to cover their cancer treatment. But he...
View ArticleFollow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid...
Daily treatment of chronic-phase chronic myeloid leukemia (CML-CP) with 50 mg dasatinib has been shown to be safe and effective in a recent follow-up report of a phase 2 clinical trial, with results...
View ArticleEveryone’s Conflicted: How Open Payments Did Little to Discourage Conflicts...
The medical field has long been wary of the influence of payments from pharmaceutical and medical device companies on physicians’ behavior. This is especially the case for the clinicians and...
View ArticleAdherence to Other Oral Medications Declines Following Introduction of Oral...
Patients’ adherence to other oral agents for comorbid chronic conditions, particularly lipid-lowering agents, significantly dropped following introduction of an oral oncolytic agent for the treatment...
View ArticleFDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
When the moment strikes, researchers like Marian McDonagh, PharmD, associate director of the evidence-based practice center at the Oregon Health and Science University, Portland, turn away from the...
View ArticleGender Bias in Oncology: Q&A With Dr Narjust Duma
Narjust Duma, MD, is a thoracic oncologist and assistant professor at the University of Wisconsin Carbone Cancer Center, in Madison, Wisconsin. She is an expert in lung cancer management, sex...
View ArticleHow to Help Patients With Cancer Find Trustworthy Information Online
The internet is a key information source for individuals with cancer, and the use of both websites and social media for this purpose has been rising in recent years. Information abounds on symptoms,...
View ArticleWhen Patient-Reported Outcomes Could Pose Risks
At the 26th Annual Conference of the International Society for Quality of Life Research, 2 groups of US Food and Drug Administration (FDA)-affiliated researchers presented abstracts for studies aiming...
View ArticlePopular Genetic Tests Miss Many Cancer-Associated Genetic Variants,...
The last few years have seen millions of people sending saliva samples to private companies for DNA analysis to better understand their risks of developing disease. Yet such direct-to-consumer (DTC)...
View ArticleReporting Mechanisms for Conflict of Interest Disclosures in Medicine Need...
A highly anticipated paper written by officials from the American Society of Clinical Oncology (ASCO) concluded that authors disclosed more research/consulting payments when submitting their...
View ArticleHow Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Because phase 1 of drug development is mostly about safety assessment, these trials are typically not designed to assess drug benefit. While the reporting of this information can be beneficial when...
View ArticleAsciminib Shows Clinical Activity for Pretreated CML in Phase 1 Trial
Asciminib appeared to have clinical activity in a population of heavily pretreated patients with chronic myeloid leukemia (CML) who had developed resistance or unacceptable toxicity during treatment...
View ArticleThe FDA Approval Process Needs Refinement, Not a Total Overhaul
A group of studies, editorials, and exposés have been published this week that criticize the US Food and Drug Administration’s (FDA’s) role as gatekeeper for new therapies. And, while some of the...
View Article